The recent partnership between Oura and Eli Lilly has raised considerable attention across the healthcare industry. At first glance, it looks like another collaboration between a technology company and a pharmaceutical manufacturer. However, looking deeper, it signals a broader transformation that could introduce new aspects on how patients are monitored throughout their treatment journey. … Continue reading From Wearables to Real-World Evidence: Are We Ready for Consumer-Generated Health Data?
Category: Methodology
The Practical Applications of AI in Real-World Evidence Studies
Artificial intelligence has become a very frequently discussed topic also in real-world evidence (RWE) research, registries, and clinical data science. Conferences, publications, and industry reports routinely highlight AI as a transformative force capable of accelerating evidence generation, improving data quality, and expanding the utility of healthcare data. However, much of this discussion remains high… Continue reading The Practical Applications of AI in Real-World Evidence Studies
What “Innovative” Really Means in Real-World Evidence Research?
In my recent job search, I came across a recurring requirement in many roles related to evidence generation, real-world evidence (RWE), and observational research: experience with innovative studies. The phrase appeared so consistently that it eventually made me pause and reflect on the studies I have worked on throughout my career. Were those… Continue reading What “Innovative” Really Means in Real-World Evidence Research?
Data feasibility in Healthcare: Comparing fit-for-purpose and fit-for-training
Healthcare organizations are investing heavily in both real-world evidence (RWE) studies and artificial intelligence (AI). At first glance, these two fields seem to rely on the same raw material: large healthcare datasets drawn from electronic health records (EHRs), claims databases, registries, genomics, imaging, and patient-generated data. Because the source data often overlaps, it is tempting… Continue reading Data feasibility in Healthcare: Comparing fit-for-purpose and fit-for-training
When the Real World Emerges from the Trial Shadow: Cardiovascular RWE at an Inflection Point
by Mathieu Ghadanfar, MD, FESC, FAHA Cardiovascular medicine has entered an era of extraordinary randomized evidence. DAPA-HF, EMPEROR-Reduced, EMPA-KIDNEY, the SELECT trial (1, 2, 3): each enrolling tens of thousands of patients, each reshaping guidelines. And yet the questions that dominate daily clinical decision-making remain unanswered by any of them. No large randomized… Continue reading When the Real World Emerges from the Trial Shadow: Cardiovascular RWE at an Inflection Point